Post by gomnkd on May 3, 2015 15:00:25 GMT -5
Through friends and family, I checked with three endos all in Atlanta.
1) Checked two months back, this endo hasn't heard of Afrezza, talked about an inhaled insulin that flopped. Worried about costs and patient affordability
2) Dr Darwin Brown has started prescribing Afrezza since last 2 weeks
3) Another endo also has started prescribing recently and has this to say "it is a good bolus insulin, easy to use, would recommend if normal lungs"
I think we are slowly but surely seeing uptake. This is a pattern that is going to be repeated across this country. I also think that prescriptions are not concentrated with just a few endos. This would mean that those endos who are prescribing to 1 or 2 pts will ramp it up once they see good results. So a journey of 1000 miles begins with one step.
----------------------------------------------------------------------------------------------------------------------------------------------------------
Someone asked about RAA uptake in the other thread. I did some research a week back as introduction of Humalog mirrors Afrezza in some ways.
When Humalog was introduced, Humulin and others dominated the market. Humalog uptake is stunning. Humulin peaked later and then slowly lost mkt share.
Attachment Deleted
The one is green is what would be Afrezza sales if we mimicked Humalog (I doubled to account for increased diabetic pt count). Again not considering pre-diabetic, increased dosage etc. It does provide a benchmark. Humalog sales are from SEC filings.
1) Checked two months back, this endo hasn't heard of Afrezza, talked about an inhaled insulin that flopped. Worried about costs and patient affordability
2) Dr Darwin Brown has started prescribing Afrezza since last 2 weeks
3) Another endo also has started prescribing recently and has this to say "it is a good bolus insulin, easy to use, would recommend if normal lungs"
I think we are slowly but surely seeing uptake. This is a pattern that is going to be repeated across this country. I also think that prescriptions are not concentrated with just a few endos. This would mean that those endos who are prescribing to 1 or 2 pts will ramp it up once they see good results. So a journey of 1000 miles begins with one step.
----------------------------------------------------------------------------------------------------------------------------------------------------------
Someone asked about RAA uptake in the other thread. I did some research a week back as introduction of Humalog mirrors Afrezza in some ways.
When Humalog was introduced, Humulin and others dominated the market. Humalog uptake is stunning. Humulin peaked later and then slowly lost mkt share.
Attachment Deleted
The one is green is what would be Afrezza sales if we mimicked Humalog (I doubled to account for increased diabetic pt count). Again not considering pre-diabetic, increased dosage etc. It does provide a benchmark. Humalog sales are from SEC filings.
